Global Peptide and Oligonucleotide CDMO Market Growth (Status and Outlook) 2023-2029
The report requires updating with new data and is sent in 48 hours after order is placed.
According to our (LP Info Research) latest study, the global Peptide and Oligonucleotide CDMO market size was valued at US$ 1565.2 million in 2022. With growing demand in downstream market and recovery from influence of COVID-19 and the Russia-Ukraine War, the Peptide and Oligonucleotide CDMO is forecast to a readjusted size of US$ 3123.4 million by 2029 with a CAGR of 10.4% during review period.
The research report highlights the growth potential of the global Peptide and Oligonucleotide CDMO market. With recovery from influence of COVID-19 and the Russia-Ukraine War, Peptide and Oligonucleotide CDMO are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Peptide and Oligonucleotide CDMO. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Peptide and Oligonucleotide CDMO market.
Key Features:
The report on Peptide and Oligonucleotide CDMO market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Peptide and Oligonucleotide CDMO market. It may include historical data, market segmentation by Type (e.g., Peptide CDMO, Oligonucleotide CDMO), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Peptide and Oligonucleotide CDMO market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Peptide and Oligonucleotide CDMO market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Peptide and Oligonucleotide CDMO industry. This include advancements in Peptide and Oligonucleotide CDMO technology, Peptide and Oligonucleotide CDMO new entrants, Peptide and Oligonucleotide CDMO new investment, and other innovations that are shaping the future of Peptide and Oligonucleotide CDMO.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Peptide and Oligonucleotide CDMO market. It includes factors influencing customer ' purchasing decisions, preferences for Peptide and Oligonucleotide CDMO product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Peptide and Oligonucleotide CDMO market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Peptide and Oligonucleotide CDMO market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Peptide and Oligonucleotide CDMO market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Peptide and Oligonucleotide CDMO industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Peptide and Oligonucleotide CDMO market.
Market Segmentation:
Peptide and Oligonucleotide CDMO market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Segmentation by type
According to our (LP Info Research) latest study, the global Peptide and Oligonucleotide CDMO market size was valued at US$ 1565.2 million in 2022. With growing demand in downstream market and recovery from influence of COVID-19 and the Russia-Ukraine War, the Peptide and Oligonucleotide CDMO is forecast to a readjusted size of US$ 3123.4 million by 2029 with a CAGR of 10.4% during review period.
The research report highlights the growth potential of the global Peptide and Oligonucleotide CDMO market. With recovery from influence of COVID-19 and the Russia-Ukraine War, Peptide and Oligonucleotide CDMO are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Peptide and Oligonucleotide CDMO. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Peptide and Oligonucleotide CDMO market.
Key Features:
The report on Peptide and Oligonucleotide CDMO market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Peptide and Oligonucleotide CDMO market. It may include historical data, market segmentation by Type (e.g., Peptide CDMO, Oligonucleotide CDMO), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Peptide and Oligonucleotide CDMO market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Peptide and Oligonucleotide CDMO market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Peptide and Oligonucleotide CDMO industry. This include advancements in Peptide and Oligonucleotide CDMO technology, Peptide and Oligonucleotide CDMO new entrants, Peptide and Oligonucleotide CDMO new investment, and other innovations that are shaping the future of Peptide and Oligonucleotide CDMO.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Peptide and Oligonucleotide CDMO market. It includes factors influencing customer ' purchasing decisions, preferences for Peptide and Oligonucleotide CDMO product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Peptide and Oligonucleotide CDMO market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Peptide and Oligonucleotide CDMO market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Peptide and Oligonucleotide CDMO market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Peptide and Oligonucleotide CDMO industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Peptide and Oligonucleotide CDMO market.
Market Segmentation:
Peptide and Oligonucleotide CDMO market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Segmentation by type
- Peptide CDMO
- Oligonucleotide CDMO
- Pharmaceutical and Biotechnology Companies
- Research Institutes
- Others
- Americas
- United States
- Canada
- Mexico
- Brazil
- APAC
- China
- Japan
- Korea
- Southeast Asia
- India
- Australia
- Europe
- Germany
- France
- UK
- Italy
- Russia
- Middle East & Africa
- Egypt
- South Africa
- Israel
- Turkey
- GCC Countries
- Lonza Group Ltd.
- Thermo Fisher Scientific Inc.
- Merck KGaA
- Catalent, Inc.
- Genscript Biotech Corporation
- Polypeptide Group
- Bachem Holding AG
- Wuxi Apptec Co., Ltd.
- Ajinomoto Co., Inc.
- Rentschler Biopharma SE
- Corden Pharma GmbH
- Senn Chemicals AG
- Almac Group
- Lonza Custom Manufacturing
- Creative Peptides
- Swiss Customized Synthesis
- Syngene
- Eurogentec
1 SCOPE OF THE REPORT
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Peptide and Oligonucleotide CDMO Market Size 2018-2029
2.1.2 Peptide and Oligonucleotide CDMO Market Size CAGR by Region 2018 VS 2022 VS 2029
2.2 Peptide and Oligonucleotide CDMO Segment by Type
2.2.1 Peptide CDMO
2.2.2 Oligonucleotide CDMO
2.3 Peptide and Oligonucleotide CDMO Market Size by Type
2.3.1 Peptide and Oligonucleotide CDMO Market Size CAGR by Type (2018 VS 2022 VS 2029)
2.3.2 Global Peptide and Oligonucleotide CDMO Market Size Market Share by Type (2018-2023)
2.4 Peptide and Oligonucleotide CDMO Segment by Application
2.4.1 Pharmaceutical and Biotechnology Companies
2.4.2 Research Institutes
2.4.3 Others
2.5 Peptide and Oligonucleotide CDMO Market Size by Application
2.5.1 Peptide and Oligonucleotide CDMO Market Size CAGR by Application (2018 VS 2022 VS 2029)
2.5.2 Global Peptide and Oligonucleotide CDMO Market Size Market Share by Application (2018-2023)
3 PEPTIDE AND OLIGONUCLEOTIDE CDMO MARKET SIZE BY PLAYER
3.1 Peptide and Oligonucleotide CDMO Market Size Market Share by Players
3.1.1 Global Peptide and Oligonucleotide CDMO Revenue by Players (2018-2023)
3.1.2 Global Peptide and Oligonucleotide CDMO Revenue Market Share by Players (2018-2023)
3.2 Global Peptide and Oligonucleotide CDMO Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 PEPTIDE AND OLIGONUCLEOTIDE CDMO BY REGIONS
4.1 Peptide and Oligonucleotide CDMO Market Size by Regions (2018-2023)
4.2 Americas Peptide and Oligonucleotide CDMO Market Size Growth (2018-2023)
4.3 APAC Peptide and Oligonucleotide CDMO Market Size Growth (2018-2023)
4.4 Europe Peptide and Oligonucleotide CDMO Market Size Growth (2018-2023)
4.5 Middle East & Africa Peptide and Oligonucleotide CDMO Market Size Growth (2018-2023)
5 AMERICAS
5.1 Americas Peptide and Oligonucleotide CDMO Market Size by Country (2018-2023)
5.2 Americas Peptide and Oligonucleotide CDMO Market Size by Type (2018-2023)
5.3 Americas Peptide and Oligonucleotide CDMO Market Size by Application (2018-2023)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Peptide and Oligonucleotide CDMO Market Size by Region (2018-2023)
6.2 APAC Peptide and Oligonucleotide CDMO Market Size by Type (2018-2023)
6.3 APAC Peptide and Oligonucleotide CDMO Market Size by Application (2018-2023)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Peptide and Oligonucleotide CDMO by Country (2018-2023)
7.2 Europe Peptide and Oligonucleotide CDMO Market Size by Type (2018-2023)
7.3 Europe Peptide and Oligonucleotide CDMO Market Size by Application (2018-2023)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Peptide and Oligonucleotide CDMO by Region (2018-2023)
8.2 Middle East & Africa Peptide and Oligonucleotide CDMO Market Size by Type (2018-2023)
8.3 Middle East & Africa Peptide and Oligonucleotide CDMO Market Size by Application (2018-2023)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL PEPTIDE AND OLIGONUCLEOTIDE CDMO MARKET FORECAST
10.1 Global Peptide and Oligonucleotide CDMO Forecast by Regions (2024-2029)
10.1.1 Global Peptide and Oligonucleotide CDMO Forecast by Regions (2024-2029)
10.1.2 Americas Peptide and Oligonucleotide CDMO Forecast
10.1.3 APAC Peptide and Oligonucleotide CDMO Forecast
10.1.4 Europe Peptide and Oligonucleotide CDMO Forecast
10.1.5 Middle East & Africa Peptide and Oligonucleotide CDMO Forecast
10.2 Americas Peptide and Oligonucleotide CDMO Forecast by Country (2024-2029)
10.2.1 United States Peptide and Oligonucleotide CDMO Market Forecast
10.2.2 Canada Peptide and Oligonucleotide CDMO Market Forecast
10.2.3 Mexico Peptide and Oligonucleotide CDMO Market Forecast
10.2.4 Brazil Peptide and Oligonucleotide CDMO Market Forecast
10.3 APAC Peptide and Oligonucleotide CDMO Forecast by Region (2024-2029)
10.3.1 China Peptide and Oligonucleotide CDMO Market Forecast
10.3.2 Japan Peptide and Oligonucleotide CDMO Market Forecast
10.3.3 Korea Peptide and Oligonucleotide CDMO Market Forecast
10.3.4 Southeast Asia Peptide and Oligonucleotide CDMO Market Forecast
10.3.5 India Peptide and Oligonucleotide CDMO Market Forecast
10.3.6 Australia Peptide and Oligonucleotide CDMO Market Forecast
10.4 Europe Peptide and Oligonucleotide CDMO Forecast by Country (2024-2029)
10.4.1 Germany Peptide and Oligonucleotide CDMO Market Forecast
10.4.2 France Peptide and Oligonucleotide CDMO Market Forecast
10.4.3 UK Peptide and Oligonucleotide CDMO Market Forecast
10.4.4 Italy Peptide and Oligonucleotide CDMO Market Forecast
10.4.5 Russia Peptide and Oligonucleotide CDMO Market Forecast
10.5 Middle East & Africa Peptide and Oligonucleotide CDMO Forecast by Region (2024-2029)
10.5.1 Egypt Peptide and Oligonucleotide CDMO Market Forecast
10.5.2 South Africa Peptide and Oligonucleotide CDMO Market Forecast
10.5.3 Israel Peptide and Oligonucleotide CDMO Market Forecast
10.5.4 Turkey Peptide and Oligonucleotide CDMO Market Forecast
10.5.5 GCC Countries Peptide and Oligonucleotide CDMO Market Forecast
10.6 Global Peptide and Oligonucleotide CDMO Forecast by Type (2024-2029)
10.7 Global Peptide and Oligonucleotide CDMO Forecast by Application (2024-2029)
11 KEY PLAYERS ANALYSIS
11.1 Lonza Group Ltd.
11.1.1 Lonza Group Ltd. Company Information
11.1.2 Lonza Group Ltd. Peptide and Oligonucleotide CDMO Product Offered
11.1.3 Lonza Group Ltd. Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.1.4 Lonza Group Ltd. Main Business Overview
11.1.5 Lonza Group Ltd. Latest Developments
11.2 Thermo Fisher Scientific Inc.
11.2.1 Thermo Fisher Scientific Inc. Company Information
11.2.2 Thermo Fisher Scientific Inc. Peptide and Oligonucleotide CDMO Product Offered
11.2.3 Thermo Fisher Scientific Inc. Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.2.4 Thermo Fisher Scientific Inc. Main Business Overview
11.2.5 Thermo Fisher Scientific Inc. Latest Developments
11.3 Merck KGaA
11.3.1 Merck KGaA Company Information
11.3.2 Merck KGaA Peptide and Oligonucleotide CDMO Product Offered
11.3.3 Merck KGaA Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.3.4 Merck KGaA Main Business Overview
11.3.5 Merck KGaA Latest Developments
11.4 Catalent, Inc.
11.4.1 Catalent, Inc. Company Information
11.4.2 Catalent, Inc. Peptide and Oligonucleotide CDMO Product Offered
11.4.3 Catalent, Inc. Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.4.4 Catalent, Inc. Main Business Overview
11.4.5 Catalent, Inc. Latest Developments
11.5 Genscript Biotech Corporation
11.5.1 Genscript Biotech Corporation Company Information
11.5.2 Genscript Biotech Corporation Peptide and Oligonucleotide CDMO Product Offered
11.5.3 Genscript Biotech Corporation Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.5.4 Genscript Biotech Corporation Main Business Overview
11.5.5 Genscript Biotech Corporation Latest Developments
11.6 Polypeptide Group
11.6.1 Polypeptide Group Company Information
11.6.2 Polypeptide Group Peptide and Oligonucleotide CDMO Product Offered
11.6.3 Polypeptide Group Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.6.4 Polypeptide Group Main Business Overview
11.6.5 Polypeptide Group Latest Developments
11.7 Bachem Holding AG
11.7.1 Bachem Holding AG Company Information
11.7.2 Bachem Holding AG Peptide and Oligonucleotide CDMO Product Offered
11.7.3 Bachem Holding AG Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.7.4 Bachem Holding AG Main Business Overview
11.7.5 Bachem Holding AG Latest Developments
11.8 Wuxi Apptec Co., Ltd.
11.8.1 Wuxi Apptec Co., Ltd. Company Information
11.8.2 Wuxi Apptec Co., Ltd. Peptide and Oligonucleotide CDMO Product Offered
11.8.3 Wuxi Apptec Co., Ltd. Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.8.4 Wuxi Apptec Co., Ltd. Main Business Overview
11.8.5 Wuxi Apptec Co., Ltd. Latest Developments
11.9 Ajinomoto Co., Inc.
11.9.1 Ajinomoto Co., Inc. Company Information
11.9.2 Ajinomoto Co., Inc. Peptide and Oligonucleotide CDMO Product Offered
11.9.3 Ajinomoto Co., Inc. Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.9.4 Ajinomoto Co., Inc. Main Business Overview
11.9.5 Ajinomoto Co., Inc. Latest Developments
11.10 Rentschler Biopharma SE
11.10.1 Rentschler Biopharma SE Company Information
11.10.2 Rentschler Biopharma SE Peptide and Oligonucleotide CDMO Product Offered
11.10.3 Rentschler Biopharma SE Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.10.4 Rentschler Biopharma SE Main Business Overview
11.10.5 Rentschler Biopharma SE Latest Developments
11.11 Corden Pharma GmbH
11.11.1 Corden Pharma GmbH Company Information
11.11.2 Corden Pharma GmbH Peptide and Oligonucleotide CDMO Product Offered
11.11.3 Corden Pharma GmbH Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.11.4 Corden Pharma GmbH Main Business Overview
11.11.5 Corden Pharma GmbH Latest Developments
11.12 Senn Chemicals AG
11.12.1 Senn Chemicals AG Company Information
11.12.2 Senn Chemicals AG Peptide and Oligonucleotide CDMO Product Offered
11.12.3 Senn Chemicals AG Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.12.4 Senn Chemicals AG Main Business Overview
11.12.5 Senn Chemicals AG Latest Developments
11.13 Almac Group
11.13.1 Almac Group Company Information
11.13.2 Almac Group Peptide and Oligonucleotide CDMO Product Offered
11.13.3 Almac Group Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.13.4 Almac Group Main Business Overview
11.13.5 Almac Group Latest Developments
11.14 Lonza Custom Manufacturing
11.14.1 Lonza Custom Manufacturing Company Information
11.14.2 Lonza Custom Manufacturing Peptide and Oligonucleotide CDMO Product Offered
11.14.3 Lonza Custom Manufacturing Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.14.4 Lonza Custom Manufacturing Main Business Overview
11.14.5 Lonza Custom Manufacturing Latest Developments
11.15 Creative Peptides
11.15.1 Creative Peptides Company Information
11.15.2 Creative Peptides Peptide and Oligonucleotide CDMO Product Offered
11.15.3 Creative Peptides Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.15.4 Creative Peptides Main Business Overview
11.15.5 Creative Peptides Latest Developments
11.16 Swiss Customized Synthesis
11.16.1 Swiss Customized Synthesis Company Information
11.16.2 Swiss Customized Synthesis Peptide and Oligonucleotide CDMO Product Offered
11.16.3 Swiss Customized Synthesis Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.16.4 Swiss Customized Synthesis Main Business Overview
11.16.5 Swiss Customized Synthesis Latest Developments
11.17 Syngene
11.17.1 Syngene Company Information
11.17.2 Syngene Peptide and Oligonucleotide CDMO Product Offered
11.17.3 Syngene Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.17.4 Syngene Main Business Overview
11.17.5 Syngene Latest Developments
11.18 Eurogentec
11.18.1 Eurogentec Company Information
11.18.2 Eurogentec Peptide and Oligonucleotide CDMO Product Offered
11.18.3 Eurogentec Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.18.4 Eurogentec Main Business Overview
11.18.5 Eurogentec Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 EXECUTIVE SUMMARY
2.1 World Market Overview
2.1.1 Global Peptide and Oligonucleotide CDMO Market Size 2018-2029
2.1.2 Peptide and Oligonucleotide CDMO Market Size CAGR by Region 2018 VS 2022 VS 2029
2.2 Peptide and Oligonucleotide CDMO Segment by Type
2.2.1 Peptide CDMO
2.2.2 Oligonucleotide CDMO
2.3 Peptide and Oligonucleotide CDMO Market Size by Type
2.3.1 Peptide and Oligonucleotide CDMO Market Size CAGR by Type (2018 VS 2022 VS 2029)
2.3.2 Global Peptide and Oligonucleotide CDMO Market Size Market Share by Type (2018-2023)
2.4 Peptide and Oligonucleotide CDMO Segment by Application
2.4.1 Pharmaceutical and Biotechnology Companies
2.4.2 Research Institutes
2.4.3 Others
2.5 Peptide and Oligonucleotide CDMO Market Size by Application
2.5.1 Peptide and Oligonucleotide CDMO Market Size CAGR by Application (2018 VS 2022 VS 2029)
2.5.2 Global Peptide and Oligonucleotide CDMO Market Size Market Share by Application (2018-2023)
3 PEPTIDE AND OLIGONUCLEOTIDE CDMO MARKET SIZE BY PLAYER
3.1 Peptide and Oligonucleotide CDMO Market Size Market Share by Players
3.1.1 Global Peptide and Oligonucleotide CDMO Revenue by Players (2018-2023)
3.1.2 Global Peptide and Oligonucleotide CDMO Revenue Market Share by Players (2018-2023)
3.2 Global Peptide and Oligonucleotide CDMO Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 PEPTIDE AND OLIGONUCLEOTIDE CDMO BY REGIONS
4.1 Peptide and Oligonucleotide CDMO Market Size by Regions (2018-2023)
4.2 Americas Peptide and Oligonucleotide CDMO Market Size Growth (2018-2023)
4.3 APAC Peptide and Oligonucleotide CDMO Market Size Growth (2018-2023)
4.4 Europe Peptide and Oligonucleotide CDMO Market Size Growth (2018-2023)
4.5 Middle East & Africa Peptide and Oligonucleotide CDMO Market Size Growth (2018-2023)
5 AMERICAS
5.1 Americas Peptide and Oligonucleotide CDMO Market Size by Country (2018-2023)
5.2 Americas Peptide and Oligonucleotide CDMO Market Size by Type (2018-2023)
5.3 Americas Peptide and Oligonucleotide CDMO Market Size by Application (2018-2023)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Peptide and Oligonucleotide CDMO Market Size by Region (2018-2023)
6.2 APAC Peptide and Oligonucleotide CDMO Market Size by Type (2018-2023)
6.3 APAC Peptide and Oligonucleotide CDMO Market Size by Application (2018-2023)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 EUROPE
7.1 Europe Peptide and Oligonucleotide CDMO by Country (2018-2023)
7.2 Europe Peptide and Oligonucleotide CDMO Market Size by Type (2018-2023)
7.3 Europe Peptide and Oligonucleotide CDMO Market Size by Application (2018-2023)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 MIDDLE EAST & AFRICA
8.1 Middle East & Africa Peptide and Oligonucleotide CDMO by Region (2018-2023)
8.2 Middle East & Africa Peptide and Oligonucleotide CDMO Market Size by Type (2018-2023)
8.3 Middle East & Africa Peptide and Oligonucleotide CDMO Market Size by Application (2018-2023)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 MARKET DRIVERS, CHALLENGES AND TRENDS
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 GLOBAL PEPTIDE AND OLIGONUCLEOTIDE CDMO MARKET FORECAST
10.1 Global Peptide and Oligonucleotide CDMO Forecast by Regions (2024-2029)
10.1.1 Global Peptide and Oligonucleotide CDMO Forecast by Regions (2024-2029)
10.1.2 Americas Peptide and Oligonucleotide CDMO Forecast
10.1.3 APAC Peptide and Oligonucleotide CDMO Forecast
10.1.4 Europe Peptide and Oligonucleotide CDMO Forecast
10.1.5 Middle East & Africa Peptide and Oligonucleotide CDMO Forecast
10.2 Americas Peptide and Oligonucleotide CDMO Forecast by Country (2024-2029)
10.2.1 United States Peptide and Oligonucleotide CDMO Market Forecast
10.2.2 Canada Peptide and Oligonucleotide CDMO Market Forecast
10.2.3 Mexico Peptide and Oligonucleotide CDMO Market Forecast
10.2.4 Brazil Peptide and Oligonucleotide CDMO Market Forecast
10.3 APAC Peptide and Oligonucleotide CDMO Forecast by Region (2024-2029)
10.3.1 China Peptide and Oligonucleotide CDMO Market Forecast
10.3.2 Japan Peptide and Oligonucleotide CDMO Market Forecast
10.3.3 Korea Peptide and Oligonucleotide CDMO Market Forecast
10.3.4 Southeast Asia Peptide and Oligonucleotide CDMO Market Forecast
10.3.5 India Peptide and Oligonucleotide CDMO Market Forecast
10.3.6 Australia Peptide and Oligonucleotide CDMO Market Forecast
10.4 Europe Peptide and Oligonucleotide CDMO Forecast by Country (2024-2029)
10.4.1 Germany Peptide and Oligonucleotide CDMO Market Forecast
10.4.2 France Peptide and Oligonucleotide CDMO Market Forecast
10.4.3 UK Peptide and Oligonucleotide CDMO Market Forecast
10.4.4 Italy Peptide and Oligonucleotide CDMO Market Forecast
10.4.5 Russia Peptide and Oligonucleotide CDMO Market Forecast
10.5 Middle East & Africa Peptide and Oligonucleotide CDMO Forecast by Region (2024-2029)
10.5.1 Egypt Peptide and Oligonucleotide CDMO Market Forecast
10.5.2 South Africa Peptide and Oligonucleotide CDMO Market Forecast
10.5.3 Israel Peptide and Oligonucleotide CDMO Market Forecast
10.5.4 Turkey Peptide and Oligonucleotide CDMO Market Forecast
10.5.5 GCC Countries Peptide and Oligonucleotide CDMO Market Forecast
10.6 Global Peptide and Oligonucleotide CDMO Forecast by Type (2024-2029)
10.7 Global Peptide and Oligonucleotide CDMO Forecast by Application (2024-2029)
11 KEY PLAYERS ANALYSIS
11.1 Lonza Group Ltd.
11.1.1 Lonza Group Ltd. Company Information
11.1.2 Lonza Group Ltd. Peptide and Oligonucleotide CDMO Product Offered
11.1.3 Lonza Group Ltd. Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.1.4 Lonza Group Ltd. Main Business Overview
11.1.5 Lonza Group Ltd. Latest Developments
11.2 Thermo Fisher Scientific Inc.
11.2.1 Thermo Fisher Scientific Inc. Company Information
11.2.2 Thermo Fisher Scientific Inc. Peptide and Oligonucleotide CDMO Product Offered
11.2.3 Thermo Fisher Scientific Inc. Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.2.4 Thermo Fisher Scientific Inc. Main Business Overview
11.2.5 Thermo Fisher Scientific Inc. Latest Developments
11.3 Merck KGaA
11.3.1 Merck KGaA Company Information
11.3.2 Merck KGaA Peptide and Oligonucleotide CDMO Product Offered
11.3.3 Merck KGaA Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.3.4 Merck KGaA Main Business Overview
11.3.5 Merck KGaA Latest Developments
11.4 Catalent, Inc.
11.4.1 Catalent, Inc. Company Information
11.4.2 Catalent, Inc. Peptide and Oligonucleotide CDMO Product Offered
11.4.3 Catalent, Inc. Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.4.4 Catalent, Inc. Main Business Overview
11.4.5 Catalent, Inc. Latest Developments
11.5 Genscript Biotech Corporation
11.5.1 Genscript Biotech Corporation Company Information
11.5.2 Genscript Biotech Corporation Peptide and Oligonucleotide CDMO Product Offered
11.5.3 Genscript Biotech Corporation Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.5.4 Genscript Biotech Corporation Main Business Overview
11.5.5 Genscript Biotech Corporation Latest Developments
11.6 Polypeptide Group
11.6.1 Polypeptide Group Company Information
11.6.2 Polypeptide Group Peptide and Oligonucleotide CDMO Product Offered
11.6.3 Polypeptide Group Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.6.4 Polypeptide Group Main Business Overview
11.6.5 Polypeptide Group Latest Developments
11.7 Bachem Holding AG
11.7.1 Bachem Holding AG Company Information
11.7.2 Bachem Holding AG Peptide and Oligonucleotide CDMO Product Offered
11.7.3 Bachem Holding AG Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.7.4 Bachem Holding AG Main Business Overview
11.7.5 Bachem Holding AG Latest Developments
11.8 Wuxi Apptec Co., Ltd.
11.8.1 Wuxi Apptec Co., Ltd. Company Information
11.8.2 Wuxi Apptec Co., Ltd. Peptide and Oligonucleotide CDMO Product Offered
11.8.3 Wuxi Apptec Co., Ltd. Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.8.4 Wuxi Apptec Co., Ltd. Main Business Overview
11.8.5 Wuxi Apptec Co., Ltd. Latest Developments
11.9 Ajinomoto Co., Inc.
11.9.1 Ajinomoto Co., Inc. Company Information
11.9.2 Ajinomoto Co., Inc. Peptide and Oligonucleotide CDMO Product Offered
11.9.3 Ajinomoto Co., Inc. Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.9.4 Ajinomoto Co., Inc. Main Business Overview
11.9.5 Ajinomoto Co., Inc. Latest Developments
11.10 Rentschler Biopharma SE
11.10.1 Rentschler Biopharma SE Company Information
11.10.2 Rentschler Biopharma SE Peptide and Oligonucleotide CDMO Product Offered
11.10.3 Rentschler Biopharma SE Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.10.4 Rentschler Biopharma SE Main Business Overview
11.10.5 Rentschler Biopharma SE Latest Developments
11.11 Corden Pharma GmbH
11.11.1 Corden Pharma GmbH Company Information
11.11.2 Corden Pharma GmbH Peptide and Oligonucleotide CDMO Product Offered
11.11.3 Corden Pharma GmbH Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.11.4 Corden Pharma GmbH Main Business Overview
11.11.5 Corden Pharma GmbH Latest Developments
11.12 Senn Chemicals AG
11.12.1 Senn Chemicals AG Company Information
11.12.2 Senn Chemicals AG Peptide and Oligonucleotide CDMO Product Offered
11.12.3 Senn Chemicals AG Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.12.4 Senn Chemicals AG Main Business Overview
11.12.5 Senn Chemicals AG Latest Developments
11.13 Almac Group
11.13.1 Almac Group Company Information
11.13.2 Almac Group Peptide and Oligonucleotide CDMO Product Offered
11.13.3 Almac Group Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.13.4 Almac Group Main Business Overview
11.13.5 Almac Group Latest Developments
11.14 Lonza Custom Manufacturing
11.14.1 Lonza Custom Manufacturing Company Information
11.14.2 Lonza Custom Manufacturing Peptide and Oligonucleotide CDMO Product Offered
11.14.3 Lonza Custom Manufacturing Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.14.4 Lonza Custom Manufacturing Main Business Overview
11.14.5 Lonza Custom Manufacturing Latest Developments
11.15 Creative Peptides
11.15.1 Creative Peptides Company Information
11.15.2 Creative Peptides Peptide and Oligonucleotide CDMO Product Offered
11.15.3 Creative Peptides Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.15.4 Creative Peptides Main Business Overview
11.15.5 Creative Peptides Latest Developments
11.16 Swiss Customized Synthesis
11.16.1 Swiss Customized Synthesis Company Information
11.16.2 Swiss Customized Synthesis Peptide and Oligonucleotide CDMO Product Offered
11.16.3 Swiss Customized Synthesis Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.16.4 Swiss Customized Synthesis Main Business Overview
11.16.5 Swiss Customized Synthesis Latest Developments
11.17 Syngene
11.17.1 Syngene Company Information
11.17.2 Syngene Peptide and Oligonucleotide CDMO Product Offered
11.17.3 Syngene Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.17.4 Syngene Main Business Overview
11.17.5 Syngene Latest Developments
11.18 Eurogentec
11.18.1 Eurogentec Company Information
11.18.2 Eurogentec Peptide and Oligonucleotide CDMO Product Offered
11.18.3 Eurogentec Peptide and Oligonucleotide CDMO Revenue, Gross Margin and Market Share (2018-2023)
11.18.4 Eurogentec Main Business Overview
11.18.5 Eurogentec Latest Developments
12 RESEARCH FINDINGS AND CONCLUSION
LIST OF TABLES
Table 1. Peptide and Oligonucleotide CDMO Market Size CAGR by Region (2018 VS 2022 VS 2029) & ($ Millions)
Table 2. Major Players of Peptide CDMO
Table 3. Major Players of Oligonucleotide CDMO
Table 4. Peptide and Oligonucleotide CDMO Market Size CAGR by Type (2018 VS 2022 VS 2029) & ($ Millions)
Table 5. Global Peptide and Oligonucleotide CDMO Market Size by Type (2018-2023) & ($ Millions)
Table 6. Global Peptide and Oligonucleotide CDMO Market Size Market Share by Type (2018-2023)
Table 7. Peptide and Oligonucleotide CDMO Market Size CAGR by Application (2018 VS 2022 VS 2029) & ($ Millions)
Table 8. Global Peptide and Oligonucleotide CDMO Market Size by Application (2018-2023) & ($ Millions)
Table 9. Global Peptide and Oligonucleotide CDMO Market Size Market Share by Application (2018-2023)
Table 10. Global Peptide and Oligonucleotide CDMO Revenue by Players (2018-2023) & ($ Millions)
Table 11. Global Peptide and Oligonucleotide CDMO Revenue Market Share by Player (2018-2023)
Table 12. Peptide and Oligonucleotide CDMO Key Players Head office and Products Offered
Table 13. Peptide and Oligonucleotide CDMO Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
Table 14. New Products and Potential Entrants
Table 15. Mergers & Acquisitions, Expansion
Table 16. Global Peptide and Oligonucleotide CDMO Market Size by Regions 2018-2023 & ($ Millions)
Table 17. Global Peptide and Oligonucleotide CDMO Market Size Market Share by Regions (2018-2023)
Table 18. Global Peptide and Oligonucleotide CDMO Revenue by Country/Region (2018-2023) & ($ millions)
Table 19. Global Peptide and Oligonucleotide CDMO Revenue Market Share by Country/Region (2018-2023)
Table 20. Americas Peptide and Oligonucleotide CDMO Market Size by Country (2018-2023) & ($ Millions)
Table 21. Americas Peptide and Oligonucleotide CDMO Market Size Market Share by Country (2018-2023)
Table 22. Americas Peptide and Oligonucleotide CDMO Market Size by Type (2018-2023) & ($ Millions)
Table 23. Americas Peptide and Oligonucleotide CDMO Market Size Market Share by Type (2018-2023)
Table 24. Americas Peptide and Oligonucleotide CDMO Market Size by Application (2018-2023) & ($ Millions)
Table 25. Americas Peptide and Oligonucleotide CDMO Market Size Market Share by Application (2018-2023)
Table 26. APAC Peptide and Oligonucleotide CDMO Market Size by Region (2018-2023) & ($ Millions)
Table 27. APAC Peptide and Oligonucleotide CDMO Market Size Market Share by Region (2018-2023)
Table 28. APAC Peptide and Oligonucleotide CDMO Market Size by Type (2018-2023) & ($ Millions)
Table 29. APAC Peptide and Oligonucleotide CDMO Market Size Market Share by Type (2018-2023)
Table 30. APAC Peptide and Oligonucleotide CDMO Market Size by Application (2018-2023) & ($ Millions)
Table 31. APAC Peptide and Oligonucleotide CDMO Market Size Market Share by Application (2018-2023)
Table 32. Europe Peptide and Oligonucleotide CDMO Market Size by Country (2018-2023) & ($ Millions)
Table 33. Europe Peptide and Oligonucleotide CDMO Market Size Market Share by Country (2018-2023)
Table 34. Europe Peptide and Oligonucleotide CDMO Market Size by Type (2018-2023) & ($ Millions)
Table 35. Europe Peptide and Oligonucleotide CDMO Market Size Market Share by Type (2018-2023)
Table 36. Europe Peptide and Oligonucleotide CDMO Market Size by Application (2018-2023) & ($ Millions)
Table 37. Europe Peptide and Oligonucleotide CDMO Market Size Market Share by Application (2018-2023)
Table 38. Middle East & Africa Peptide and Oligonucleotide CDMO Market Size by Region (2018-2023) & ($ Millions)
Table 39. Middle East & Africa Peptide and Oligonucleotide CDMO Market Size Market Share by Region (2018-2023)
Table 40. Middle East & Africa Peptide and Oligonucleotide CDMO Market Size by Type (2018-2023) & ($ Millions)
Table 41. Middle East & Africa Peptide and Oligonucleotide CDMO Market Size Market Share by Type (2018-2023)
Table 42. Middle East & Africa Peptide and Oligonucleotide CDMO Market Size by Application (2018-2023) & ($ Millions)
Table 43. Middle East & Africa Peptide and Oligonucleotide CDMO Market Size Market Share by Application (2018-2023)
Table 44. Key Market Drivers & Growth Opportunities of Peptide and Oligonucleotide CDMO
Table 45. Key Market Challenges & Risks of Peptide and Oligonucleotide CDMO
Table 46. Key Industry Trends of Peptide and Oligonucleotide CDMO
Table 47. Global Peptide and Oligonucleotide CDMO Market Size Forecast by Regions (2024-2029) & ($ Millions)
Table 48. Global Peptide and Oligonucleotide CDMO Market Size Market Share Forecast by Regions (2024-2029)
Table 49. Global Peptide and Oligonucleotide CDMO Market Size Forecast by Type (2024-2029) & ($ Millions)
Table 50. Global Peptide and Oligonucleotide CDMO Market Size Forecast by Application (2024-2029) & ($ Millions)
Table 51. Lonza Group Ltd. Details, Company Type, Peptide and Oligonucleotide CDMO Area Served and Its Competitors
Table 52. Lonza Group Ltd. Peptide and Oligonucleotide CDMO Product Offered
Table 53. Lonza Group Ltd. Peptide and Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 54. Lonza Group Ltd. Main Business
Table 55. Lonza Group Ltd. Latest Developments
Table 56. Thermo Fisher Scientific Inc. Details, Company Type, Peptide and Oligonucleotide CDMO Area Served and Its Competitors
Table 57. Thermo Fisher Scientific Inc. Peptide and Oligonucleotide CDMO Product Offered
Table 58. Thermo Fisher Scientific Inc. Main Business
Table 59. Thermo Fisher Scientific Inc. Peptide and Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 60. Thermo Fisher Scientific Inc. Latest Developments
Table 61. Merck KGaA Details, Company Type, Peptide and Oligonucleotide CDMO Area Served and Its Competitors
Table 62. Merck KGaA Peptide and Oligonucleotide CDMO Product Offered
Table 63. Merck KGaA Main Business
Table 64. Merck KGaA Peptide and Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 65. Merck KGaA Latest Developments
Table 66. Catalent, Inc. Details, Company Type, Peptide and Oligonucleotide CDMO Area Served and Its Competitors
Table 67. Catalent, Inc. Peptide and Oligonucleotide CDMO Product Offered
Table 68. Catalent, Inc. Main Business
Table 69. Catalent, Inc. Peptide and Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 70. Catalent, Inc. Latest Developments
Table 71. Genscript Biotech Corporation Details, Company Type, Peptide and Oligonucleotide CDMO Area Served and Its Competitors
Table 72. Genscript Biotech Corporation Peptide and Oligonucleotide CDMO Product Offered
Table 73. Genscript Biotech Corporation Main Business
Table 74. Genscript Biotech Corporation Peptide and Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 75. Genscript Biotech Corporation Latest Developments
Table 76. Polypeptide Group Details, Company Type, Peptide and Oligonucleotide CDMO Area Served and Its Competitors
Table 77. Polypeptide Group Peptide and Oligonucleotide CDMO Product Offered
Table 78. Polypeptide Group Main Business
Table 79. Polypeptide Group Peptide and Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 80. Polypeptide Group Latest Developments
Table 81. Bachem Holding AG Details, Company Type, Peptide and Oligonucleotide CDMO Area Served and Its Competitors
Table 82. Bachem Holding AG Peptide and Oligonucleotide CDMO Product Offered
Table 83. Bachem Holding AG Main Business
Table 84. Bachem Holding AG Peptide and Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 85. Bachem Holding AG Latest Developments
Table 86. Wuxi Apptec Co., Ltd. Details, Company Type, Peptide and Oligonucleotide CDMO Area Served and Its Competitors
Table 87. Wuxi Apptec Co., Ltd. Peptide and Oligonucleotide CDMO Product Offered
Table 88. Wuxi Apptec Co., Ltd. Main Business
Table 89. Wuxi Apptec Co., Ltd. Peptide and Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 90. Wuxi Apptec Co., Ltd. Latest Developments
Table 91. Ajinomoto Co., Inc. Details, Company Type, Peptide and Oligonucleotide CDMO Area Served and Its Competitors
Table 92. Ajinomoto Co., Inc. Peptide and Oligonucleotide CDMO Product Offered
Table 93. Ajinomoto Co., Inc. Main Business
Table 94. Ajinomoto Co., Inc. Peptide and Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 95. Ajinomoto Co., Inc. Latest Developments
Table 96. Rentschler Biopharma SE Details, Company Type, Peptide and Oligonucleotide CDMO Area Served and Its Competitors
Table 97. Rentschler Biopharma SE Peptide and Oligonucleotide CDMO Product Offered
Table 98. Rentschler Biopharma SE Main Business
Table 99. Rentschler Biopharma SE Peptide and Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 100. Rentschler Biopharma SE Latest Developments
Table 101. Corden Pharma GmbH Details, Company Type, Peptide and Oligonucleotide CDMO Area Served and Its Competitors
Table 102. Corden Pharma GmbH Peptide and Oligonucleotide CDMO Product Offered
Table 103. Corden Pharma GmbH Peptide and Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 104. Corden Pharma GmbH Main Business
Table 105. Corden Pharma GmbH Latest Developments
Table 106. Senn Chemicals AG Details, Company Type, Peptide and Oligonucleotide CDMO Area Served and Its Competitors
Table 107. Senn Chemicals AG Peptide and Oligonucleotide CDMO Product Offered
Table 108. Senn Chemicals AG Main Business
Table 109. Senn Chemicals AG Peptide and Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 110. Senn Chemicals AG Latest Developments
Table 111. Almac Group Details, Company Type, Peptide and Oligonucleotide CDMO Area Served and Its Competitors
Table 112. Almac Group Peptide and Oligonucleotide CDMO Product Offered
Table 113. Almac Group Main Business
Table 114. Almac Group Peptide and Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 115. Almac Group Latest Developments
Table 116. Lonza Custom Manufacturing Details, Company Type, Peptide and Oligonucleotide CDMO Area Served and Its Competitors
Table 117. Lonza Custom Manufacturing Peptide and Oligonucleotide CDMO Product Offered
Table 118. Lonza Custom Manufacturing Main Business
Table 119. Lonza Custom Manufacturing Peptide and Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 120. Lonza Custom Manufacturing Latest Developments
Table 121. Creative Peptides Details, Company Type, Peptide and Oligonucleotide CDMO Area Served and Its Competitors
Table 122. Creative Peptides Peptide and Oligonucleotide CDMO Product Offered
Table 123. Creative Peptides Main Business
Table 124. Creative Peptides Peptide and Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 125. Creative Peptides Latest Developments
Table 126. Swiss Customized Synthesis Details, Company Type, Peptide and Oligonucleotide CDMO Area Served and Its Competitors
Table 127. Swiss Customized Synthesis Peptide and Oligonucleotide CDMO Product Offered
Table 128. Swiss Customized Synthesis Main Business
Table 129. Swiss Customized Synthesis Peptide and Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 130. Swiss Customized Synthesis Latest Developments
Table 131. Syngene Details, Company Type, Peptide and Oligonucleotide CDMO Area Served and Its Competitors
Table 132. Syngene Peptide and Oligonucleotide CDMO Product Offered
Table 133. Syngene Main Business
Table 134. Syngene Peptide and Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 135. Syngene Latest Developments
Table 136. Eurogentec Details, Company Type, Peptide and Oligonucleotide CDMO Area Served and Its Competitors
Table 137. Eurogentec Peptide and Oligonucleotide CDMO Product Offered
Table 138. Eurogentec Main Business
Table 139. Eurogentec Peptide and Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 140. Eurogentec Latest Developments
Table 1. Peptide and Oligonucleotide CDMO Market Size CAGR by Region (2018 VS 2022 VS 2029) & ($ Millions)
Table 2. Major Players of Peptide CDMO
Table 3. Major Players of Oligonucleotide CDMO
Table 4. Peptide and Oligonucleotide CDMO Market Size CAGR by Type (2018 VS 2022 VS 2029) & ($ Millions)
Table 5. Global Peptide and Oligonucleotide CDMO Market Size by Type (2018-2023) & ($ Millions)
Table 6. Global Peptide and Oligonucleotide CDMO Market Size Market Share by Type (2018-2023)
Table 7. Peptide and Oligonucleotide CDMO Market Size CAGR by Application (2018 VS 2022 VS 2029) & ($ Millions)
Table 8. Global Peptide and Oligonucleotide CDMO Market Size by Application (2018-2023) & ($ Millions)
Table 9. Global Peptide and Oligonucleotide CDMO Market Size Market Share by Application (2018-2023)
Table 10. Global Peptide and Oligonucleotide CDMO Revenue by Players (2018-2023) & ($ Millions)
Table 11. Global Peptide and Oligonucleotide CDMO Revenue Market Share by Player (2018-2023)
Table 12. Peptide and Oligonucleotide CDMO Key Players Head office and Products Offered
Table 13. Peptide and Oligonucleotide CDMO Concentration Ratio (CR3, CR5 and CR10) & (2021-2023)
Table 14. New Products and Potential Entrants
Table 15. Mergers & Acquisitions, Expansion
Table 16. Global Peptide and Oligonucleotide CDMO Market Size by Regions 2018-2023 & ($ Millions)
Table 17. Global Peptide and Oligonucleotide CDMO Market Size Market Share by Regions (2018-2023)
Table 18. Global Peptide and Oligonucleotide CDMO Revenue by Country/Region (2018-2023) & ($ millions)
Table 19. Global Peptide and Oligonucleotide CDMO Revenue Market Share by Country/Region (2018-2023)
Table 20. Americas Peptide and Oligonucleotide CDMO Market Size by Country (2018-2023) & ($ Millions)
Table 21. Americas Peptide and Oligonucleotide CDMO Market Size Market Share by Country (2018-2023)
Table 22. Americas Peptide and Oligonucleotide CDMO Market Size by Type (2018-2023) & ($ Millions)
Table 23. Americas Peptide and Oligonucleotide CDMO Market Size Market Share by Type (2018-2023)
Table 24. Americas Peptide and Oligonucleotide CDMO Market Size by Application (2018-2023) & ($ Millions)
Table 25. Americas Peptide and Oligonucleotide CDMO Market Size Market Share by Application (2018-2023)
Table 26. APAC Peptide and Oligonucleotide CDMO Market Size by Region (2018-2023) & ($ Millions)
Table 27. APAC Peptide and Oligonucleotide CDMO Market Size Market Share by Region (2018-2023)
Table 28. APAC Peptide and Oligonucleotide CDMO Market Size by Type (2018-2023) & ($ Millions)
Table 29. APAC Peptide and Oligonucleotide CDMO Market Size Market Share by Type (2018-2023)
Table 30. APAC Peptide and Oligonucleotide CDMO Market Size by Application (2018-2023) & ($ Millions)
Table 31. APAC Peptide and Oligonucleotide CDMO Market Size Market Share by Application (2018-2023)
Table 32. Europe Peptide and Oligonucleotide CDMO Market Size by Country (2018-2023) & ($ Millions)
Table 33. Europe Peptide and Oligonucleotide CDMO Market Size Market Share by Country (2018-2023)
Table 34. Europe Peptide and Oligonucleotide CDMO Market Size by Type (2018-2023) & ($ Millions)
Table 35. Europe Peptide and Oligonucleotide CDMO Market Size Market Share by Type (2018-2023)
Table 36. Europe Peptide and Oligonucleotide CDMO Market Size by Application (2018-2023) & ($ Millions)
Table 37. Europe Peptide and Oligonucleotide CDMO Market Size Market Share by Application (2018-2023)
Table 38. Middle East & Africa Peptide and Oligonucleotide CDMO Market Size by Region (2018-2023) & ($ Millions)
Table 39. Middle East & Africa Peptide and Oligonucleotide CDMO Market Size Market Share by Region (2018-2023)
Table 40. Middle East & Africa Peptide and Oligonucleotide CDMO Market Size by Type (2018-2023) & ($ Millions)
Table 41. Middle East & Africa Peptide and Oligonucleotide CDMO Market Size Market Share by Type (2018-2023)
Table 42. Middle East & Africa Peptide and Oligonucleotide CDMO Market Size by Application (2018-2023) & ($ Millions)
Table 43. Middle East & Africa Peptide and Oligonucleotide CDMO Market Size Market Share by Application (2018-2023)
Table 44. Key Market Drivers & Growth Opportunities of Peptide and Oligonucleotide CDMO
Table 45. Key Market Challenges & Risks of Peptide and Oligonucleotide CDMO
Table 46. Key Industry Trends of Peptide and Oligonucleotide CDMO
Table 47. Global Peptide and Oligonucleotide CDMO Market Size Forecast by Regions (2024-2029) & ($ Millions)
Table 48. Global Peptide and Oligonucleotide CDMO Market Size Market Share Forecast by Regions (2024-2029)
Table 49. Global Peptide and Oligonucleotide CDMO Market Size Forecast by Type (2024-2029) & ($ Millions)
Table 50. Global Peptide and Oligonucleotide CDMO Market Size Forecast by Application (2024-2029) & ($ Millions)
Table 51. Lonza Group Ltd. Details, Company Type, Peptide and Oligonucleotide CDMO Area Served and Its Competitors
Table 52. Lonza Group Ltd. Peptide and Oligonucleotide CDMO Product Offered
Table 53. Lonza Group Ltd. Peptide and Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 54. Lonza Group Ltd. Main Business
Table 55. Lonza Group Ltd. Latest Developments
Table 56. Thermo Fisher Scientific Inc. Details, Company Type, Peptide and Oligonucleotide CDMO Area Served and Its Competitors
Table 57. Thermo Fisher Scientific Inc. Peptide and Oligonucleotide CDMO Product Offered
Table 58. Thermo Fisher Scientific Inc. Main Business
Table 59. Thermo Fisher Scientific Inc. Peptide and Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 60. Thermo Fisher Scientific Inc. Latest Developments
Table 61. Merck KGaA Details, Company Type, Peptide and Oligonucleotide CDMO Area Served and Its Competitors
Table 62. Merck KGaA Peptide and Oligonucleotide CDMO Product Offered
Table 63. Merck KGaA Main Business
Table 64. Merck KGaA Peptide and Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 65. Merck KGaA Latest Developments
Table 66. Catalent, Inc. Details, Company Type, Peptide and Oligonucleotide CDMO Area Served and Its Competitors
Table 67. Catalent, Inc. Peptide and Oligonucleotide CDMO Product Offered
Table 68. Catalent, Inc. Main Business
Table 69. Catalent, Inc. Peptide and Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 70. Catalent, Inc. Latest Developments
Table 71. Genscript Biotech Corporation Details, Company Type, Peptide and Oligonucleotide CDMO Area Served and Its Competitors
Table 72. Genscript Biotech Corporation Peptide and Oligonucleotide CDMO Product Offered
Table 73. Genscript Biotech Corporation Main Business
Table 74. Genscript Biotech Corporation Peptide and Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 75. Genscript Biotech Corporation Latest Developments
Table 76. Polypeptide Group Details, Company Type, Peptide and Oligonucleotide CDMO Area Served and Its Competitors
Table 77. Polypeptide Group Peptide and Oligonucleotide CDMO Product Offered
Table 78. Polypeptide Group Main Business
Table 79. Polypeptide Group Peptide and Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 80. Polypeptide Group Latest Developments
Table 81. Bachem Holding AG Details, Company Type, Peptide and Oligonucleotide CDMO Area Served and Its Competitors
Table 82. Bachem Holding AG Peptide and Oligonucleotide CDMO Product Offered
Table 83. Bachem Holding AG Main Business
Table 84. Bachem Holding AG Peptide and Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 85. Bachem Holding AG Latest Developments
Table 86. Wuxi Apptec Co., Ltd. Details, Company Type, Peptide and Oligonucleotide CDMO Area Served and Its Competitors
Table 87. Wuxi Apptec Co., Ltd. Peptide and Oligonucleotide CDMO Product Offered
Table 88. Wuxi Apptec Co., Ltd. Main Business
Table 89. Wuxi Apptec Co., Ltd. Peptide and Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 90. Wuxi Apptec Co., Ltd. Latest Developments
Table 91. Ajinomoto Co., Inc. Details, Company Type, Peptide and Oligonucleotide CDMO Area Served and Its Competitors
Table 92. Ajinomoto Co., Inc. Peptide and Oligonucleotide CDMO Product Offered
Table 93. Ajinomoto Co., Inc. Main Business
Table 94. Ajinomoto Co., Inc. Peptide and Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 95. Ajinomoto Co., Inc. Latest Developments
Table 96. Rentschler Biopharma SE Details, Company Type, Peptide and Oligonucleotide CDMO Area Served and Its Competitors
Table 97. Rentschler Biopharma SE Peptide and Oligonucleotide CDMO Product Offered
Table 98. Rentschler Biopharma SE Main Business
Table 99. Rentschler Biopharma SE Peptide and Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 100. Rentschler Biopharma SE Latest Developments
Table 101. Corden Pharma GmbH Details, Company Type, Peptide and Oligonucleotide CDMO Area Served and Its Competitors
Table 102. Corden Pharma GmbH Peptide and Oligonucleotide CDMO Product Offered
Table 103. Corden Pharma GmbH Peptide and Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 104. Corden Pharma GmbH Main Business
Table 105. Corden Pharma GmbH Latest Developments
Table 106. Senn Chemicals AG Details, Company Type, Peptide and Oligonucleotide CDMO Area Served and Its Competitors
Table 107. Senn Chemicals AG Peptide and Oligonucleotide CDMO Product Offered
Table 108. Senn Chemicals AG Main Business
Table 109. Senn Chemicals AG Peptide and Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 110. Senn Chemicals AG Latest Developments
Table 111. Almac Group Details, Company Type, Peptide and Oligonucleotide CDMO Area Served and Its Competitors
Table 112. Almac Group Peptide and Oligonucleotide CDMO Product Offered
Table 113. Almac Group Main Business
Table 114. Almac Group Peptide and Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 115. Almac Group Latest Developments
Table 116. Lonza Custom Manufacturing Details, Company Type, Peptide and Oligonucleotide CDMO Area Served and Its Competitors
Table 117. Lonza Custom Manufacturing Peptide and Oligonucleotide CDMO Product Offered
Table 118. Lonza Custom Manufacturing Main Business
Table 119. Lonza Custom Manufacturing Peptide and Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 120. Lonza Custom Manufacturing Latest Developments
Table 121. Creative Peptides Details, Company Type, Peptide and Oligonucleotide CDMO Area Served and Its Competitors
Table 122. Creative Peptides Peptide and Oligonucleotide CDMO Product Offered
Table 123. Creative Peptides Main Business
Table 124. Creative Peptides Peptide and Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 125. Creative Peptides Latest Developments
Table 126. Swiss Customized Synthesis Details, Company Type, Peptide and Oligonucleotide CDMO Area Served and Its Competitors
Table 127. Swiss Customized Synthesis Peptide and Oligonucleotide CDMO Product Offered
Table 128. Swiss Customized Synthesis Main Business
Table 129. Swiss Customized Synthesis Peptide and Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 130. Swiss Customized Synthesis Latest Developments
Table 131. Syngene Details, Company Type, Peptide and Oligonucleotide CDMO Area Served and Its Competitors
Table 132. Syngene Peptide and Oligonucleotide CDMO Product Offered
Table 133. Syngene Main Business
Table 134. Syngene Peptide and Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 135. Syngene Latest Developments
Table 136. Eurogentec Details, Company Type, Peptide and Oligonucleotide CDMO Area Served and Its Competitors
Table 137. Eurogentec Peptide and Oligonucleotide CDMO Product Offered
Table 138. Eurogentec Main Business
Table 139. Eurogentec Peptide and Oligonucleotide CDMO Revenue ($ million), Gross Margin and Market Share (2018-2023)
Table 140. Eurogentec Latest Developments
LIST OF FIGURES
Figure 1. Peptide and Oligonucleotide CDMO Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Peptide and Oligonucleotide CDMO Market Size Growth Rate 2018-2029 ($ Millions)
Figure 6. Peptide and Oligonucleotide CDMO Sales by Geographic Region (2018, 2022 & 2029) & ($ millions)
Figure 7. Peptide and Oligonucleotide CDMO Sales Market Share by Country/Region (2022)
Figure 8. Peptide and Oligonucleotide CDMO Sales Market Share by Country/Region (2018, 2022 & 2029)
Figure 9. Global Peptide and Oligonucleotide CDMO Market Size Market Share by Type in 2022
Figure 10. Peptide and Oligonucleotide CDMO in Pharmaceutical and Biotechnology Companies
Figure 11. Global Peptide and Oligonucleotide CDMO Market: Pharmaceutical and Biotechnology Companies (2018-2023) & ($ Millions)
Figure 12. Peptide and Oligonucleotide CDMO in Research Institutes
Figure 13. Global Peptide and Oligonucleotide CDMO Market: Research Institutes (2018-2023) & ($ Millions)
Figure 14. Peptide and Oligonucleotide CDMO in Others
Figure 15. Global Peptide and Oligonucleotide CDMO Market: Others (2018-2023) & ($ Millions)
Figure 16. Global Peptide and Oligonucleotide CDMO Market Size Market Share by Application in 2022
Figure 17. Global Peptide and Oligonucleotide CDMO Revenue Market Share by Player in 2022
Figure 18. Global Peptide and Oligonucleotide CDMO Market Size Market Share by Regions (2018-2023)
Figure 19. Americas Peptide and Oligonucleotide CDMO Market Size 2018-2023 ($ Millions)
Figure 20. APAC Peptide and Oligonucleotide CDMO Market Size 2018-2023 ($ Millions)
Figure 21. Europe Peptide and Oligonucleotide CDMO Market Size 2018-2023 ($ Millions)
Figure 22. Middle East & Africa Peptide and Oligonucleotide CDMO Market Size 2018-2023 ($ Millions)
Figure 23. Americas Peptide and Oligonucleotide CDMO Value Market Share by Country in 2022
Figure 24. United States Peptide and Oligonucleotide CDMO Market Size Growth 2018-2023 ($ Millions)
Figure 25. Canada Peptide and Oligonucleotide CDMO Market Size Growth 2018-2023 ($ Millions)
Figure 26. Mexico Peptide and Oligonucleotide CDMO Market Size Growth 2018-2023 ($ Millions)
Figure 27. Brazil Peptide and Oligonucleotide CDMO Market Size Growth 2018-2023 ($ Millions)
Figure 28. APAC Peptide and Oligonucleotide CDMO Market Size Market Share by Region in 2022
Figure 29. APAC Peptide and Oligonucleotide CDMO Market Size Market Share by Type in 2022
Figure 30. APAC Peptide and Oligonucleotide CDMO Market Size Market Share by Application in 2022
Figure 31. China Peptide and Oligonucleotide CDMO Market Size Growth 2018-2023 ($ Millions)
Figure 32. Japan Peptide and Oligonucleotide CDMO Market Size Growth 2018-2023 ($ Millions)
Figure 33. Korea Peptide and Oligonucleotide CDMO Market Size Growth 2018-2023 ($ Millions)
Figure 34. Southeast Asia Peptide and Oligonucleotide CDMO Market Size Growth 2018-2023 ($ Millions)
Figure 35. India Peptide and Oligonucleotide CDMO Market Size Growth 2018-2023 ($ Millions)
Figure 36. Australia Peptide and Oligonucleotide CDMO Market Size Growth 2018-2023 ($ Millions)
Figure 37. Europe Peptide and Oligonucleotide CDMO Market Size Market Share by Country in 2022
Figure 38. Europe Peptide and Oligonucleotide CDMO Market Size Market Share by Type (2018-2023)
Figure 39. Europe Peptide and Oligonucleotide CDMO Market Size Market Share by Application (2018-2023)
Figure 40. Germany Peptide and Oligonucleotide CDMO Market Size Growth 2018-2023 ($ Millions)
Figure 41. France Peptide and Oligonucleotide CDMO Market Size Growth 2018-2023 ($ Millions)
Figure 42. UK Peptide and Oligonucleotide CDMO Market Size Growth 2018-2023 ($ Millions)
Figure 43. Italy Peptide and Oligonucleotide CDMO Market Size Growth 2018-2023 ($ Millions)
Figure 44. Russia Peptide and Oligonucleotide CDMO Market Size Growth 2018-2023 ($ Millions)
Figure 45. Middle East & Africa Peptide and Oligonucleotide CDMO Market Size Market Share by Region (2018-2023)
Figure 46. Middle East & Africa Peptide and Oligonucleotide CDMO Market Size Market Share by Type (2018-2023)
Figure 47. Middle East & Africa Peptide and Oligonucleotide CDMO Market Size Market Share by Application (2018-2023)
Figure 48. Egypt Peptide and Oligonucleotide CDMO Market Size Growth 2018-2023 ($ Millions)
Figure 49. South Africa Peptide and Oligonucleotide CDMO Market Size Growth 2018-2023 ($ Millions)
Figure 50. Israel Peptide and Oligonucleotide CDMO Market Size Growth 2018-2023 ($ Millions)
Figure 51. Turkey Peptide and Oligonucleotide CDMO Market Size Growth 2018-2023 ($ Millions)
Figure 52. GCC Country Peptide and Oligonucleotide CDMO Market Size Growth 2018-2023 ($ Millions)
Figure 53. Americas Peptide and Oligonucleotide CDMO Market Size 2024-2029 ($ Millions)
Figure 54. APAC Peptide and Oligonucleotide CDMO Market Size 2024-2029 ($ Millions)
Figure 55. Europe Peptide and Oligonucleotide CDMO Market Size 2024-2029 ($ Millions)
Figure 56. Middle East & Africa Peptide and Oligonucleotide CDMO Market Size 2024-2029 ($ Millions)
Figure 57. United States Peptide and Oligonucleotide CDMO Market Size 2024-2029 ($ Millions)
Figure 58. Canada Peptide and Oligonucleotide CDMO Market Size 2024-2029 ($ Millions)
Figure 59. Mexico Peptide and Oligonucleotide CDMO Market Size 2024-2029 ($ Millions)
Figure 60. Brazil Peptide and Oligonucleotide CDMO Market Size 2024-2029 ($ Millions)
Figure 61. China Peptide and Oligonucleotide CDMO Market Size 2024-2029 ($ Millions)
Figure 62. Japan Peptide and Oligonucleotide CDMO Market Size 2024-2029 ($ Millions)
Figure 63. Korea Peptide and Oligonucleotide CDMO Market Size 2024-2029 ($ Millions)
Figure 64. Southeast Asia Peptide and Oligonucleotide CDMO Market Size 2024-2029 ($ Millions)
Figure 65. India Peptide and Oligonucleotide CDMO Market Size 2024-2029 ($ Millions)
Figure 66. Australia Peptide and Oligonucleotide CDMO Market Size 2024-2029 ($ Millions)
Figure 67. Germany Peptide and Oligonucleotide CDMO Market Size 2024-2029 ($ Millions)
Figure 68. France Peptide and Oligonucleotide CDMO Market Size 2024-2029 ($ Millions)
Figure 69. UK Peptide and Oligonucleotide CDMO Market Size 2024-2029 ($ Millions)
Figure 70. Italy Peptide and Oligonucleotide CDMO Market Size 2024-2029 ($ Millions)
Figure 71. Russia Peptide and Oligonucleotide CDMO Market Size 2024-2029 ($ Millions)
Figure 72. Spain Peptide and Oligonucleotide CDMO Market Size 2024-2029 ($ Millions)
Figure 73. Egypt Peptide and Oligonucleotide CDMO Market Size 2024-2029 ($ Millions)
Figure 74. South Africa Peptide and Oligonucleotide CDMO Market Size 2024-2029 ($ Millions)
Figure 75. Israel Peptide and Oligonucleotide CDMO Market Size 2024-2029 ($ Millions)
Figure 76. Turkey Peptide and Oligonucleotide CDMO Market Size 2024-2029 ($ Millions)
Figure 77. GCC Countries Peptide and Oligonucleotide CDMO Market Size 2024-2029 ($ Millions)
Figure 78. Global Peptide and Oligonucleotide CDMO Market Size Market Share Forecast by Type (2024-2029)
Figure 79. Global Peptide and Oligonucleotide CDMO Market Size Market Share Forecast by Application (2024-2029)
Figure 1. Peptide and Oligonucleotide CDMO Report Years Considered
Figure 2. Research Objectives
Figure 3. Research Methodology
Figure 4. Research Process and Data Source
Figure 5. Global Peptide and Oligonucleotide CDMO Market Size Growth Rate 2018-2029 ($ Millions)
Figure 6. Peptide and Oligonucleotide CDMO Sales by Geographic Region (2018, 2022 & 2029) & ($ millions)
Figure 7. Peptide and Oligonucleotide CDMO Sales Market Share by Country/Region (2022)
Figure 8. Peptide and Oligonucleotide CDMO Sales Market Share by Country/Region (2018, 2022 & 2029)
Figure 9. Global Peptide and Oligonucleotide CDMO Market Size Market Share by Type in 2022
Figure 10. Peptide and Oligonucleotide CDMO in Pharmaceutical and Biotechnology Companies
Figure 11. Global Peptide and Oligonucleotide CDMO Market: Pharmaceutical and Biotechnology Companies (2018-2023) & ($ Millions)
Figure 12. Peptide and Oligonucleotide CDMO in Research Institutes
Figure 13. Global Peptide and Oligonucleotide CDMO Market: Research Institutes (2018-2023) & ($ Millions)
Figure 14. Peptide and Oligonucleotide CDMO in Others
Figure 15. Global Peptide and Oligonucleotide CDMO Market: Others (2018-2023) & ($ Millions)
Figure 16. Global Peptide and Oligonucleotide CDMO Market Size Market Share by Application in 2022
Figure 17. Global Peptide and Oligonucleotide CDMO Revenue Market Share by Player in 2022
Figure 18. Global Peptide and Oligonucleotide CDMO Market Size Market Share by Regions (2018-2023)
Figure 19. Americas Peptide and Oligonucleotide CDMO Market Size 2018-2023 ($ Millions)
Figure 20. APAC Peptide and Oligonucleotide CDMO Market Size 2018-2023 ($ Millions)
Figure 21. Europe Peptide and Oligonucleotide CDMO Market Size 2018-2023 ($ Millions)
Figure 22. Middle East & Africa Peptide and Oligonucleotide CDMO Market Size 2018-2023 ($ Millions)
Figure 23. Americas Peptide and Oligonucleotide CDMO Value Market Share by Country in 2022
Figure 24. United States Peptide and Oligonucleotide CDMO Market Size Growth 2018-2023 ($ Millions)
Figure 25. Canada Peptide and Oligonucleotide CDMO Market Size Growth 2018-2023 ($ Millions)
Figure 26. Mexico Peptide and Oligonucleotide CDMO Market Size Growth 2018-2023 ($ Millions)
Figure 27. Brazil Peptide and Oligonucleotide CDMO Market Size Growth 2018-2023 ($ Millions)
Figure 28. APAC Peptide and Oligonucleotide CDMO Market Size Market Share by Region in 2022
Figure 29. APAC Peptide and Oligonucleotide CDMO Market Size Market Share by Type in 2022
Figure 30. APAC Peptide and Oligonucleotide CDMO Market Size Market Share by Application in 2022
Figure 31. China Peptide and Oligonucleotide CDMO Market Size Growth 2018-2023 ($ Millions)
Figure 32. Japan Peptide and Oligonucleotide CDMO Market Size Growth 2018-2023 ($ Millions)
Figure 33. Korea Peptide and Oligonucleotide CDMO Market Size Growth 2018-2023 ($ Millions)
Figure 34. Southeast Asia Peptide and Oligonucleotide CDMO Market Size Growth 2018-2023 ($ Millions)
Figure 35. India Peptide and Oligonucleotide CDMO Market Size Growth 2018-2023 ($ Millions)
Figure 36. Australia Peptide and Oligonucleotide CDMO Market Size Growth 2018-2023 ($ Millions)
Figure 37. Europe Peptide and Oligonucleotide CDMO Market Size Market Share by Country in 2022
Figure 38. Europe Peptide and Oligonucleotide CDMO Market Size Market Share by Type (2018-2023)
Figure 39. Europe Peptide and Oligonucleotide CDMO Market Size Market Share by Application (2018-2023)
Figure 40. Germany Peptide and Oligonucleotide CDMO Market Size Growth 2018-2023 ($ Millions)
Figure 41. France Peptide and Oligonucleotide CDMO Market Size Growth 2018-2023 ($ Millions)
Figure 42. UK Peptide and Oligonucleotide CDMO Market Size Growth 2018-2023 ($ Millions)
Figure 43. Italy Peptide and Oligonucleotide CDMO Market Size Growth 2018-2023 ($ Millions)
Figure 44. Russia Peptide and Oligonucleotide CDMO Market Size Growth 2018-2023 ($ Millions)
Figure 45. Middle East & Africa Peptide and Oligonucleotide CDMO Market Size Market Share by Region (2018-2023)
Figure 46. Middle East & Africa Peptide and Oligonucleotide CDMO Market Size Market Share by Type (2018-2023)
Figure 47. Middle East & Africa Peptide and Oligonucleotide CDMO Market Size Market Share by Application (2018-2023)
Figure 48. Egypt Peptide and Oligonucleotide CDMO Market Size Growth 2018-2023 ($ Millions)
Figure 49. South Africa Peptide and Oligonucleotide CDMO Market Size Growth 2018-2023 ($ Millions)
Figure 50. Israel Peptide and Oligonucleotide CDMO Market Size Growth 2018-2023 ($ Millions)
Figure 51. Turkey Peptide and Oligonucleotide CDMO Market Size Growth 2018-2023 ($ Millions)
Figure 52. GCC Country Peptide and Oligonucleotide CDMO Market Size Growth 2018-2023 ($ Millions)
Figure 53. Americas Peptide and Oligonucleotide CDMO Market Size 2024-2029 ($ Millions)
Figure 54. APAC Peptide and Oligonucleotide CDMO Market Size 2024-2029 ($ Millions)
Figure 55. Europe Peptide and Oligonucleotide CDMO Market Size 2024-2029 ($ Millions)
Figure 56. Middle East & Africa Peptide and Oligonucleotide CDMO Market Size 2024-2029 ($ Millions)
Figure 57. United States Peptide and Oligonucleotide CDMO Market Size 2024-2029 ($ Millions)
Figure 58. Canada Peptide and Oligonucleotide CDMO Market Size 2024-2029 ($ Millions)
Figure 59. Mexico Peptide and Oligonucleotide CDMO Market Size 2024-2029 ($ Millions)
Figure 60. Brazil Peptide and Oligonucleotide CDMO Market Size 2024-2029 ($ Millions)
Figure 61. China Peptide and Oligonucleotide CDMO Market Size 2024-2029 ($ Millions)
Figure 62. Japan Peptide and Oligonucleotide CDMO Market Size 2024-2029 ($ Millions)
Figure 63. Korea Peptide and Oligonucleotide CDMO Market Size 2024-2029 ($ Millions)
Figure 64. Southeast Asia Peptide and Oligonucleotide CDMO Market Size 2024-2029 ($ Millions)
Figure 65. India Peptide and Oligonucleotide CDMO Market Size 2024-2029 ($ Millions)
Figure 66. Australia Peptide and Oligonucleotide CDMO Market Size 2024-2029 ($ Millions)
Figure 67. Germany Peptide and Oligonucleotide CDMO Market Size 2024-2029 ($ Millions)
Figure 68. France Peptide and Oligonucleotide CDMO Market Size 2024-2029 ($ Millions)
Figure 69. UK Peptide and Oligonucleotide CDMO Market Size 2024-2029 ($ Millions)
Figure 70. Italy Peptide and Oligonucleotide CDMO Market Size 2024-2029 ($ Millions)
Figure 71. Russia Peptide and Oligonucleotide CDMO Market Size 2024-2029 ($ Millions)
Figure 72. Spain Peptide and Oligonucleotide CDMO Market Size 2024-2029 ($ Millions)
Figure 73. Egypt Peptide and Oligonucleotide CDMO Market Size 2024-2029 ($ Millions)
Figure 74. South Africa Peptide and Oligonucleotide CDMO Market Size 2024-2029 ($ Millions)
Figure 75. Israel Peptide and Oligonucleotide CDMO Market Size 2024-2029 ($ Millions)
Figure 76. Turkey Peptide and Oligonucleotide CDMO Market Size 2024-2029 ($ Millions)
Figure 77. GCC Countries Peptide and Oligonucleotide CDMO Market Size 2024-2029 ($ Millions)
Figure 78. Global Peptide and Oligonucleotide CDMO Market Size Market Share Forecast by Type (2024-2029)
Figure 79. Global Peptide and Oligonucleotide CDMO Market Size Market Share Forecast by Application (2024-2029)
